02/01/2026
Nature Biotechnology's 2025 research review highlights significant advancements in biotechnology, including CRISPR-based gene editing, immunotherapy
- *In Vivo Cell Therapies*: Researchers have developed in vivo strategies for chimeric antigen receptor T cell therapies, using targeted lipid nanoparticles for mRNA delivery to specific T cell subsets.
- *Genome Editing*: Novel genome-editing systems, such as retrotransposons and bridge recombinases, have shown promise for large-scale genome engineering.
- *Base Editing for Rare Diseases*: A customized lipid-nanoparticle-delivered base-editing therapy has been developed for CPS1 deficiency, a rare metabolic disease.
- *Quantum Computing in Drug Discovery*: Quantum generative models have been combined with classical drug-discovery approaches to generate compounds targeting the KRAS protein.
- *AI in Research*: Agentic AI systems are streamlining workflows, reducing human effort, and accelerating research pace.
These advancements showcase the rapid progress in biotechnology, with potential applications in treating various diseases ¹ ² ³.
Would you like to know more about:
1. How CRISPR technology is being applied in cancer treatment?
2. The role of AI in accelerating biotech research and discoveries?
Nature Biotechnology is a monthly journal publishing new concepts in biological technology of relevance to bioengineering, medicine, energy, agriculture, food ...